Nkarta (NKTX) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nkarta (NKTX) has outperformed Veraxa Biotech (VRXA) over the past year, gaining 10.2% versus a loss of 88.5%. Veraxa Biotech is the larger company by market cap ($169.7 million vs $155.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTX | VRXA |
|---|---|---|
| Share price | $2.18 | $1.20 |
| Market cap | $155.80M | $169.69M |
| 1-day change | -4.18% | 0.00% |
| YTD return | +22.70% | -88.75% |
| 1-year return | +10.19% | -88.53% |
| 5-year return | -87.62% | — |
| EPS (TTM) | $-1.58 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.72 | $27.36 |
| 52-week low | $1.70 | $1.04 |
| Distance from 52-week high | -41.53% | -95.61% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +397.89% | — |
| Average volume | 617.86K | 274.75K |
| Shares outstanding | 71.62M | 141.41M |
| Employees | 106 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed VRXA by 98.7 percentage points over the past year.
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
NKTX vs VRXA FAQ
Which is bigger, Nkarta or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $169.69M compared with $155.80M for Nkarta (NKTX).
Which stock has performed better over the past year, NKTX or VRXA?
NKTX returned +10.19% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Nkarta and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.